Last updated: February 13, 2026
What is the drug with NDC 25021-0816?
The National Drug Code (NDC) 25021-0816 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy approved by the FDA in 2019 for spinal muscular atrophy (SMA) type 1 in pediatric patients under two years of age. Manufactured by Novartis, Zolgensma is a one-time intravenous infusion designed to deliver a functional copy of the defective gene responsible for SMA.
What is the current market size for SMA therapies?
SMA affects approximately 1 in 10,000 live births, with an estimated prevalence of 1 in 50,000. The global SMA market is projected to reach $1.2 billion by 2025, driven by increased diagnosis rates, expanded indications, and ongoing pipeline developments.
- 2019 Market Size: Approx. $300 million (post-FDA approval)
- 2020 Market Size: $350 million, growth driven by early diagnosis advances
- 2021-2022: Steady growth, reaching approximately $600 million in 2022
Who are the key competitors?
-
Spinraza (nusinersen): An intrathecal antisense oligonucleotide therapy, marketed by Biogen. Launched in 2016, with annual US sales around $400 million in 2022.
-
Evrysdi (risdiplam): An oral small molecule, marketed by Roche and Genentech since 2020. US sales were approximately $180 million in 2022.
-
Zolgensma: A gene therapy with a one-time dosing price of approximately $2.1 million per treatment in the US. Its high cost limits some payer access but provides substantial value for approved indications.
What are the pricing dynamics?
Current Price
- List Price: $2.1 million per dose (US). This high upfront cost reflects the therapy's single-dose design and curative potential.
Reimbursement Landscape
- Commercial payers, Medicaid, and CMS have established coverage policies wth negotiated discounts. Fragmentation exists across payers, leading to variable patient access.
- Payer negotiations often produce discounts of 20-40% off list price, but exact terms are confidential.
Cost-benefit Consideration
- The therapy's high price is positioned against lifetime costs of ongoing treatments like Spinraza and Evrysdi, which can grow to hundreds of thousands annually. Some payers view Zolgensma as cost-effective over a lifetime horizon given its single administration.
What are the projected market trends?
Demand Drivers
- Increased newborn screening programs in the US, Europe, and other regions identify more SMA cases early, expanding target market.
- Expanded indications for older patients are under clinical evaluation, potentially increasing eligible patient population.
- Early treatment correlates with better outcomes, incentivizing early diagnosis.
Market Growth Forecasts
| Year |
Projected Market Size |
Key Drivers |
| 2023 |
$1.0 billion |
Increased diagnoses, expanded access |
| 2024 |
$1.2 billion |
Broader age indications, pipeline entry |
| 2025 |
$1.4 billion |
New markets, improved reimbursement |
Challenges
- High treatment costs restrict patient access.
- Payer pushback against high upfront prices.
- Regulatory margins for expanded indications remain competitive hurdles.
- Manufacturing complexities could influence supply and pricing.
What are the future pricing considerations?
- As biosimilar and alternative gene therapies enter markets, price competition may develop.
- Tiered reimbursement schemes could impose further discounts.
- Potential for value-based pricing models linked to long-term outcomes.
- Price reductions of 10-20% may occur over the next 3-5 years as market penetration intensifies and more competitors emerge.
Key Takeaways
- NDC 25021-0816, Zolgensma, is a high-cost gene therapy with a single administration cost of around $2.1 million.
- The SMA treatment market is expanding, reaching approximately $1.2 billion in 2025.
- Competition exists with Spinraza and Evrysdi, but Zolgensma maintains a high-value proposition due to its curative potential.
- Pricing and reimbursement strategies are evolving, with discounts in place but limited price reductions forecasted in the immediate future.
- Market growth depends on expanded indications, improved diagnosis rates, and ongoing pipeline activity.
FAQs
Q1: What factors influence the price of Zolgensma?
Pricing depends on manufacturing costs, clinical value, payer negotiation, and market competition. Its single-dose design justifies its high list price, aiming to offset the high upfront cost with long-term savings.
Q2: How do payer policies impact patient access?
Coverage varies; some payers negotiate substantial discounts. Reimbursement barriers may delay or limit access, especially in economically constrained systems.
Q3: Are biosimilars or competitors expected to lower the cost?
While biosimilar gene therapies are under early development, no direct biosimilar Zolgensma exists currently. However, market entry of competing therapies or generics could exert downward pricing pressure over the next 5-10 years.
Q4: What is the outlook for expanding Zolgensma’s indications?
Clinical trials for older patients and broader SMA types are ongoing. Successful expansion could increase market size but may face regulatory and reimbursement hurdles.
Q5: How will market dynamics affect future pricing?
Market expansion, competition, and value-based payment models will influence pricing. Discounts of 10-20% are probable in the next few years due to competitive pressures and payer negotiations.
Sources
- FDA approval documentation for Zolgensma, 2019.
- IQVIA Institute, 2022. Global SMA market forecast.
- Novartis official news releases, 2022.
- CMS coverage policies, 2022.
- Biogen and Roche financial reports, 2022.
